Arch Venture Fund XII Amends Stake in Prime Medicine

TL;DR

Arch Venture Fund XII just updated its 13D filing for Prime Medicine, adding more entities to its group. Watch this space.

AI Summary

ARCH Venture Fund XII, L.P. and its affiliates filed an amendment (No. 1) to their Schedule 13D on November 22, 2024, regarding their beneficial ownership of Prime Medicine, Inc. The filing indicates a change in the group members, with the addition of ARCH Venture Fund X Overage, L.P., ARCH Venture Fund X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners X, L.P., ARCH Venture Partners X, LLC, ARCH Venture Partners XII, L.P., and ARCH Venture Partners XII, LLC. The filing does not specify a dollar amount or a specific date of change beyond the filing date.

Why It Matters

This amendment signals a potential shift in the ownership structure or investment strategy of a significant shareholder in Prime Medicine, Inc., which could impact the company's future direction.

Risk Assessment

Risk Level: medium — Changes in beneficial ownership filings can indicate shifts in investor sentiment or strategy, potentially affecting stock price and company control.

Key Players & Entities

• ARCH Venture Fund XII, L.P. (company) — Filing entity
• Prime Medicine, Inc. (company) — Subject company
• ARCH Venture Fund X Overage, L.P. (company) — Added group member
• ARCH Venture Fund X, L.P. (company) — Added group member
• ARCH Venture Partners X Overage, L.P. (company) — Added group member
• ARCH Venture Partners X, L.P. (company) — Added group member
• ARCH Venture Partners X, LLC (company) — Added group member
• ARCH Venture Partners XII, L.P. (company) — Added group member
• ARCH Venture Partners XII, LLC (company) — Added group member
• Keith Crandell (person) — Group member

FAQ

Key Financial Figures

• $0.00001 — Inc. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securiti

Filing Documents

• arch-sch13d_18909.htm (SC 13D/A) — 425KB
• 0001072613-24-000898.txt ( ) — 427KB

Security

Item 1. Security and Issuer . This statement relates to the Common Stock, $0.00001 par value per share (the “Common Stock”), of Prime Medicine, Inc. (the “Issuer”) having its principal executive office at 21 Erie St., Cambridge, MA 02139 USA.

IDENTITY

Item 2. IDENTITY AND BACKGROUND . (a) This statement is being filed by (1) ARCH Venture Fund X, L.P. (“AVF X”), (2) ARCH Venture Partners X, L.P. (“AVP X LP”) which is the sole general partner of AVF X, (3) ARCH Venture Partners X, LLC (“AVP X LLC”) which is the sole general partner of AVP X LP and AVP X Overage LP (defined below), (4) ARCH Venture Fund X Overage, L.P. (“AVF X Overage”), (5) ARCH Venture Partners X Overage, L.P. (“AVP X Overage LP”), which is the sole general partner of AVF X Overage, (6) ARCH Venture Fund XII, L.P. (“AVF XII”), (7) ARCH Venture Partners XII, L.P. (“AVP XII LP”) which is the sole general partner of AVF XII, (8) ARCH Venture Partners XII, LLC (“AVP XII LLC”) which is the sole general partner of AVP XII LP, (9) Keith Crandell (“Crandell”), (10) Robert Nelsen (“Nelsen”), (11) Kristina Burow (“Burow”), and (12) Steven Gillis (“Gillis”, and together with Nelsen, Crandell and Burow, referred to individually as “Committee Member” or collectively as either the “AVP X Investment Committee Members” or the “AVP XII Investment Committee Members”). Each of the individuals and entities above shall be referred to herein as a “Reporting Person” and collectively as the “Reporting Persons”. (b) The business address of each of the Reporting Persons is 8755 West Higgins Road, Suite 1025, Chicago, IL, 60631. (c) The principal business of AVP X LP is to act as the general partner of AVF X, the principal business of AVP X Overage LP is to act as the general partner of AVF X Overage, and the principal business of AVP XII is to act as the general partner of AVF XII. The principal business of AVP X LLC is to act as the general partner of AVP X LP and AVF X Overage LP, and the principal business of AVP XII LLC is to act as the general partner of AVP XII

Material

Item 7. Material to be Filed as Exhibits . Exhibit 1- Agreement of Joint Filing Exhibit 2- Agreement of Joint Filing Exhibit 3- Amended and Restated Investors' Rights Agreement, dated April 20, 2021, as amended, by and among the Issuer and certain of its stockholders (incorporated by reference to Exhibit 4.1+ to the Issuer's Registration Statement on Form S-1 (File No.), as filed with the Securities and Exchange Commission on September 23, 2022) CUSIP No. 74168J101 13D Page 17 of 22 Pages Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date:November 22, 2024 ARCH VENTURE FUND X, L.P. By: ARCH Venture Partners X, L.P. its General Partner By: ARCH Venture Partners X, LLC its General Partner By: * Robert Nelsen Managing Director ARCH VENTURE PARTNERS X, L.P. By: ARCH Venture Partners X, LLC its General Partner By: * Robert Nelsen Managing Director ARCH VENTURE PARTNERS X, LLC By: * Keith Crandell Managing Director ARCH VENTURE FUND X OVERAGE, L.P. By: ARCH Venture Partners X Overage, L.P. its General Partner . By:ARCH Venture Partners X, LLC its General Partner By: * Robert Nelsen Managing Director ARCH VENTURE PARTNERS X OVERAGE, L.P. By: ARCH Venture Partners X, LLC its General Partner By: * Robert Nelsen Managing Director CUSIP No. 74168J101 13D Page 18 of 22 Pages ARCH VENTURE PARTNERS X, LLC By: * Robert Nelsen Managing Director * Kristina Burow * Keith Crandell * Steven Gillis * Robert Nelsen * By: /s/ Mark McDonnell Mark McDonnell Attorney-in-Fact * This Schedule 13D was executed by Mark McDonnell pursuant to Powers of Attorney filed as Exhibit 24 and 24.1 to the Form 3 relating to the beneficial ownership of shares of Prime Medicine, Inc. by the Reporting Persons filed with the Securities Exchange Commission on October 19, 2022 and incorporated herein in

View Full Filing

View this SC 13D/A filing on SEC EDGAR